Immunic, Inc. Rings the Closing Bell

Date & Time Dec 7, 2023 3:45pm - 4:15pm
Location Nasdaq MarketSite, 4 Times Square, New York

About This Event

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, visits the Nasdaq MarketSite in Times Square. Immunic’s lead asset, vidofludimus calcium (IMU-838), a once-daily oral small molecule drug, is currently in phase 3 and phase 2 clinical development for relapsing and progressive multiple sclerosis, respectively, and combines neuroprotective, anti-inflammatory, and anti-viral effects with an unparalleled safety and tolerability profile. The company is also developing IMU-856 for celiac disease and other gastrointestinal disorders.

In honor of the occasion, Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic, rings the Closing Bell.

Nasdaq Watch

See what's playing at Nasdaq

Watch Now